We also found that the lesser symptoms in COVID-19 patients treated with AT1R blockers were associated with lower serum cTnI levels in hypertensive COVID-19 patients treated with AT1R blockers than those not taking them. This evidence concerns the gene AGTR1 and COVID-19.